Work

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps2075

Authors: Sani Haider Kizilbash, Samuel McBrayer, John Port, Joel M. Reid, Ian Lanza, Jacob B Allred, Arnab Chakravarti, Charles Kunos, Alex A. Adjei

Institutions: Mayo Clinic, Dana-Farber Cancer Institute, National Cancer Institute

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947713247

Cites:

Cited by: 16

Related to: 10